Krystal Biotech Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $126.75
- Today's High:
- $132.43
- Open Price:
- $128.07
- 52W Low:
- $61.11
- 52W High:
- $132.43
- Prev. Close:
- $128.44
- Volume:
- 261451
Company Statistics
- Market Cap.:
- $3.60 billion
- Book Value:
- 23.346
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -13.71%
- Return on Equity TTM:
- -23.16%
Company Profile
Krystal Biotech Inc had its IPO on 2017-09-20 under the ticker symbol KRYS.
The company operates in the Healthcare sector and Biotechnology industry. Krystal Biotech Inc has a staff strength of 210 employees.
Stock update
Shares of Krystal Biotech Inc opened at $128.07 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $126.75 - $132.43, and closed at $127.34.
This is a -0.86% slip from the previous day's closing price.
A total volume of 261,451 shares were traded at the close of the day’s session.
In the last one week, shares of Krystal Biotech Inc have increased by +0.86%.
Krystal Biotech Inc's Key Ratios
Krystal Biotech Inc has a market cap of $3.60 billion, indicating a price to book ratio of 3.3819 and a price to sales ratio of 0.
In the last 12-months Krystal Biotech Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-137116992. The EBITDA ratio measures Krystal Biotech Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Krystal Biotech Inc’s operating margin was 0% while its return on assets stood at -13.71% with a return of equity of -23.16%.
In Q2, Krystal Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Krystal Biotech Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-5.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Krystal Biotech Inc’s profitability.
Krystal Biotech Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -11.4587. Its price to sales ratio in the trailing 12-months stood at 0.
Krystal Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $684.03 million
- Total Liabilities
- $23.90 million
- Operating Cash Flow
- $-15957000.00
- Capital Expenditure
- $2.79 million
- Dividend Payout Ratio
- 0%
Krystal Biotech Inc ended 2024 with $684.03 million in total assets and $0 in total liabilities. Its intangible assets were valued at $684.03 million while shareholder equity stood at $653.11 million.
Krystal Biotech Inc ended 2024 with $0 in deferred long-term liabilities, $23.90 million in other current liabilities, in common stock, $-359266000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $275.88 million and cash and short-term investments were $477.52 million. The company’s total short-term debt was $1,529,000 while long-term debt stood at $0.
Krystal Biotech Inc’s total current assets stands at $484.00 million while long-term investments were $28.41 million and short-term investments were $201.64 million. Its net receivables were $0 compared to accounts payable of $4.45 million and inventory worth $0.
In 2024, Krystal Biotech Inc's operating cash flow was $-15957000.00 while its capital expenditure stood at $2.79 million.
Comparatively, Krystal Biotech Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $127.34
- 52-Week High
- $132.43
- 52-Week Low
- $61.11
- Analyst Target Price
- $148.57
Krystal Biotech Inc stock is currently trading at $127.34 per share. It touched a 52-week high of $132.43 and a 52-week low of $132.43. Analysts tracking the stock have a 12-month average target price of $148.57.
Its 50-day moving average was $123.11 and 200-day moving average was $96.73 The short ratio stood at 5.68 indicating a short percent outstanding of 0%.
Around 1395.5% of the company’s stock are held by insiders while 8054.8% are held by institutions.
Frequently Asked Questions About Krystal Biotech Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.